Clinical trial of radiation and chemotherapy before stem cell transplant for hard-to-treat AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of total body irradiation and two chemotherapy drugs (busulfan and melphalan) given before a stem cell transplant. It is for people with acute myeloid leukemia that has come back or not responded to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 70 years old.
- You have AML that has relapsed (come back) or is refractory (didn't respond to treatment).
- You have a suitable donor for the stem cell transplant.
- Your heart, liver, and kidneys are working well enough, based on blood tests and heart tests.
- You are generally in good enough health to undergo the procedure (able to care for yourself and life expectancy at least 3 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stronger chemotherapy combination before a donor stem cell transplant for people with certain blood cancers (like AML, MDS, or CMML) that have spread to other parts of the body, such as the skin, testicles, or central nervous system. The goal is to see if this approach can improve outcomes for patients whose disease is in remission.
This trial tests a new combination of chemotherapy drugs before a stem cell transplant for people with acute myeloid leukemia (AML) in first remission who are not very fit or have other health problems. The goal is to make the transplant safer for these patients.
This trial tests a new drug combination to help people with relapsed or refractory acute myeloid leukemia (AML) get ready for a stem cell transplant. The goal is to make the transplant more effective and improve outcomes.
This trial tests a precise type of radiation called intensity modulated total marrow irradiation before a stem cell transplant. It aims to destroy cancer cells while reducing side effects for patients with high-risk leukemia or myelodysplastic syndrome.
This trial tests a new type of radiation therapy called automated total marrow and lymphoid irradiation (TMLI) given before a stem cell transplant. It's designed to treat blood cancers like leukemia and myelodysplastic syndrome by destroying cancer cells and preparing the body to accept donor stem cells.
This trial tests a stronger chemotherapy and radiation regimen before a donor stem cell transplant for people with acute myeloid leukemia or high-risk myelodysplastic syndrome. The goal is to eliminate any remaining cancer cells and improve transplant success.
Hear when a new Relapsed or Refractory Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.